Company Initial Public Offering: The lawsuit seeks to recover damages for Avalanche Biotechnologies investors under the federal securities laws To join the Avalanche Biotechnologies class action, go to the firm website at or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action, according to Market Watch. The lawsuit is pending in U.S. District Court for the Northern District of California. AAVL, -2.97% securities pursuant and/or traceable to the Company Initial Public Offering on or about July 31, 2014; and/or on the open market between July 31, 2014 and June 15, 2015, both dates inclusive of the important September 8, 2015 lead plaintiff deadline in the class action filed by the firm. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. According to the lawsuit, Defendants made materially false and/or misleading statements and failed to disclose that Phase 2a of the AVA-101 study was not designed to show any statistical significance between the active and control groups in the secondary endpoints. A class action lawsuit has already been filed. When the true details entered the market, the lawsuit claims that investors suffered damages.
(news.financializer.com). As
reported in the news.
Tagged under Company Initial Public Offering, class action topics.